Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy

International Journal of Cancer

Volumn 126, Issue 12, 2010, Pages 2935-2946

  Abbas, Sascha ^a   Beckmann, Lars ^a   Chang Claude, Jenny ^a   Hein, Rebecca ^a   Kropp, Silke ^a   Parthimos, Margie ^a   Dünnebier, Thomas ^a   Hamann, Ute ^a   Brors, Benedikt ^a   Eils, Roland ^a   Zapatka, Marc ^a   Brauch, Hiltrud ^b,c   Justenhoven, Christina ^b,c   Flesch Janys, Dieter ^d   Braendle, Wilhelm ^d   Brüning, Thomas ^e   Pesch, Beate ^e   Spickenheuer, Anee ^e   Baisch, Christian ^f   Ko, Yon Dschun ^f   Dahmen, Norbert ^g   Salazar, Ramona ^h   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Johanniter Krankenhaus   (Germany)

^g Congenics AG ^*  (Germany)

^h NONE

Author keywords

Hormone therapy; Polymorphisms; Postmenopausal breast cancer risk; Steroid hormone receptor superfamily

Indexed keywords

ANTIGESTAGEN; ESTROGEN; STEROID RECEPTOR; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CELL RECEPTOR; ESR1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MRFAP1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PEROXISOME TARGETING SIGNAL 1 RECEPTOR; PEROXISOME-TARGETING SIGNAL 1 RECEPTOR; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; HORMONE SUBSTITUTION; MENOPAUSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SURVIVAL RATE;

EID: 77951936158     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24892     Document Type: Article

References (56)

1. Horwitz K, Clarke C. Estrogens and progestins in mammary development and neoplasia. Introduction. J Mammary Gland Biol Neoplasia 1998;3:1-2.
2. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616 (Pubitemid 34498648)
3. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-433
4. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427 (Pubitemid 36999703)
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
6. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008;123:933-941
7. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600. (Pubitemid 34760816)
8. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332 (Pubitemid 30117736)
9. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491 (Pubitemid 30062864)
10. Seeger H, Mueck AO. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 2008;109:11-15
11. Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol 2008;22:2215-2228
12. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92:73-82.
13. Blumberg B, Sabbagh W, Jr, Juguilon H, Bolado J, Jr., van Meter CM, Ong ES, Evans RM. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998;12:3195-3205 (Pubitemid 28496264)
14. Gao X, Loggie BW, Nawaz Z. The roles of sex steroid receptor coregulators in cancer. Mol Cancer 2002;1:7.
15. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat May 8, 2009. [Epub ahead of print].
16. Pesch B, Ko Y, Brauch H, Hamann U, Harth V, Rabstein S, Pierl C, Fischer HP, Baisch C, Justenhoven C, Ranft U, Bruning T. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005;20:699-711.
17. Ashton K, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott R. Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 2009;116:1053-1061
18. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Toloczko-Grabarek A, Gilbert M, Edler L, Zapatka M, Eils R, Lubinski J, et al. BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat Apr 10, 2009. [Epub ahead of print].
19. Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, et al. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 1999;91:961-966
20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21: 263-265 (Pubitemid 40202029)
21. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229
22. Obreiter M, Fischer C, Chang-Claude J, Beckmann L. SDMinP: a program to control the family wise error rate using step-down minP adjusted P-values. Bioinformatics 2005;21:3183-3184 (Pubitemid 41418478)
23. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for p-value adjustment. New York: Wiley, 1993.
24. Marugo M, Bernasconi D, Miglietta L, Fazzuoli L, Ravera F, Cassulo S, Giordano G. Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSAT). J Steroid Biochem Mol Biol 1992;42:547-554
25. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-467
26. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F. Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16′ alpha-chloro-3′,17 beta-dihydroxy-estra-1′,3′,5′-(10′)triene-70 alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 1991;51:2797-2802
27. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22: 3181-3186
28. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 1995;4:523-527
29. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777-3782 (Pubitemid 27509371)
30. Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M, Holm G, Bjorntorp P, Eriksson E. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001;86:2562-2568 (Pubitemid 32545707)
31. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299 (Pubitemid 28433474)
32. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, Pasternack BS, Toniolo P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030-1038 (Pubitemid 27215486)
33. Dorgan JF, Longcope C, Stephenson HE, Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-539
34. Haiman CA, Hankinson SE, De V, I, Guillemette C, Ishibe N, Hunter DJ, Byrne C. Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat 2003;77:27-36.
35. Lillie EO, Bernstein L, Ingles SA, Gauderman WJ, Rivas GE, Gagalang V, Krontiris T, Ursin G. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res 2004;64:1237-1241
36. Slattery ML, Sweeney C, Herrick J, Wolff R, Baumgartner K, Giuliano A, Byers T. ESR1. AR, body size, and breast cancer risk in. Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat 2007;105:327-335
37. Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, Guzelian PS, Evans RM. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000;14:3014-3023
38. Mackenzie PI, Gregory PA, Gardner-Stephen DA, Lewinsky RH, Jorgensen BR, Nishiyama T, Xie W, Radominska-Pandya A. Regulation of UDP glucuronosyltransferase genes. Curr Drug Metab 2003;4:249-257
39. Falkner KC, Pinaire JA, Xiao GH, Geoghegan TE, Prough RA. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol 2001;60:611-619
40. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-14587
41. Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 2003;31:1296-1299 (Pubitemid 37310315)
42. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001;11:555-572
43. Barnes KM, Dickstein B, Cutler GB, Jr, Fojo T, Bates SE. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996;35:4820-4827
44. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 2004;21:1284-1293
45. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003;144:3382-3398
46. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 2006;15:551-558
47. Chen GG, Zeng Q, Tse GM. Estrogen and its receptors in cancer. Med Res Rev 2008;28:954-974
48. Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, DeFreese DC, Gramling BA, Evans I, White E. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1751-1759
49. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 2006;20:534-543 (Pubitemid 43292585)
50. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol 2005;19:1555-1568 (Pubitemid 41002985)
51. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006;147:4831-4842 (Pubitemid 44402189)
52. Conneely OM, Kettelberger DM, Tsai MJ, Schrader WT, O'Malley BW. The chicken progesterone receptor A and B isoforms are products of an alternate translation initiation event. J Biol Chem 1989;264:14062-14064
53. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603-1614 (Pubitemid 20137018)
54. Rebbeck TR, Troxel AB, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin JA, Strom BL. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 2007;166:1392-1399 (Pubitemid 350209049)
55. Hartge P. Participation in population studies. Epidemiology 2006;17: 252-254
56. Kropp S, Terboven T, Hedicke J, Mutschelknauss E, Slanger T, Braendle W, Berger J, Chang-Claude J, Flesch-Janys D. Good agreement between physician and self-reported hormone therapy data in a case-control study. J Clin Epidemiol 2007;60:1280-1287 (Pubitemid 350061139)